Alcon's $200M RxSight partnership aims to recapture IOL market share with adjustable presbyopic lenses. RxSight gets 30% ...
Medical Device Network on MSN
Alcon spends up to $200M to co-develop customisable cataract lenses with RxSight
The companies will combine their expertise to develop a ‘tuneable’ presbyopia-correcting intraocular lens (PCIOL) for ...
Aziz Mottiwala becomes RxSight CEO July 20 amid commercial challenges. The move follows the $200M Alcon deal for adjustable ...
Alcon and RxSight, Inc have announced a non-exclusive collaboration to jointly develop adjustable presbyopia-correcting ...
Milestone includes more than 6 million PCIOL implants worldwide, with PanOptix and Vivity leading globally in trifocal and EDOF IOLs1,* PanOptix delivers outstanding patient satisfaction and freedom ...
BENGALURU, India--(BUSINESS WIRE)--Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the launch of the Clareon ® Family of intraocular ...
Key findings from across the 21 scientific presentations on Alcon products will be presented at the meeting, including the soon-to-launch, first non-diffractive extended depth of focus AcrySof® IQ ...
MarketBeat on MSN
RxSight Q2 sales sink 20% as Alcon deal bolsters 2026 outlook
Key Points Interested in RxSight, Inc.? Here are five stocks we like better. RxSight's preliminary Q2 sales fell 20% year ...
PanOptix, the first and only advanced trifocal lens for U.S. patients undergoing cataract surgery, will be showcased in educational events and clinical data presentations First-ever analyses on IOLs ...
Please provide your email address to receive an email when new articles are posted on . The Clareon family of IOLs is now available in the U.S., with an international rollout set to take place ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results